How Long Can Allergan Keep Valeant’s Bid at Bay?
May 12 (Bloomberg) -- Bloomberg’s Drew Armstrong examines Allergan’s rejection of Valeant’s unsolicited offer and actions by the drug maker to find a different buyer other than Valeant. He speaks on Bloomberg Television’s “Market Makers.”
Most Recent Videos
Disrupting the Paper Cut Industry
15:39 - A Silicon Valley startup called Ripcord has unveiled a machine that takes stacks of paper, pulls out the staples, rapidly scans the paper and send the scans to the cloud. That seemingly inane task is done at breakneck speed. Watch what happens when Bloomberg Technology reporter Ian King tries to do the same thing. (video by Matt Gottschalk, Camen Hodges) (Source: Bloomberg)